We applied targeted MS (parallel reaction monitoring, PRM) to pre-qualify candidates for clinical ELISA assay development. Literature harvested potential biomarker candidates, for which typically no antibodies for sensitive detection in complex samples exist, were evaluated in a medium-sized patient cohort using PRM. After biomarker validation, clinical grade ELISAs were developed and tested in a larger independent patient cohort.